哈佛生物科学 HBIO 深 沪
已收盘 08-21 16:00:00 美东时间
7.48
-0.070
-0.93%
华盛通- 最 高7.64
- 今 开7.64
- 成交量 1.07万股
- 最 低 7.37
- 昨 收 7.55
- 总市值 3405.12万
- 52周最高 9.40
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 3.755
- 委 比 -19.90%
- 总股本 455.23万
- 历史最高 87.50
- 量 比 0.37
- 振 幅 3.58%
- 历史最低 2.813
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.
08-12 20:58
Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million analyst estimate.
08-11 19:03
Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 33.33 percent. This is a 40 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $22.727 millio...
08-11 19:02
Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026
On May 25, 2026, the Board of Directors (the "Board") of LENSAR, Inc. (the "Company") appointed Michael A. Rossi to serve as the Company's Interim Chief Financial Officer and principal financial officer, effective as of
05-30 04:09
哈佛生物科学重申2026年营收增长2%-4%，“维京计划”剑指年省400万美元
哈佛生物科学公司周二公布第一季度财报，并重申全年业绩指引。尽管一季度营收同比略有下滑，公司仍维持2026全年营收增长2%至4%的预期，同时“维京计划”制造整...
05-13 03:07
Harvard Bioscience shares are trading lower after the company reported mixed Q1 financial results.
Harvard Bioscience shares are trading lower after the company reported mixed Q1...
05-12 23:53
Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.
05-12 19:34
Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.62) by 46.77 percent. This is a 230 percent decrease over losses of $(0.10) per share from
05-12 19:33
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
